Advancing Care With Exon Skipping Therapies for Duchenne Muscular Dystrophy
Prosensa's Video Animation on Exon Skipping
AOC for the treatment of Duchenne muscular dystrophy in exon 44 skippers
New Exon Skipping Drug in Clinical Development for Duchenne Muscular Dystrophy
Hanugen Therapeutics on exon skipping or the tech it uses to treat Duchenne Muscular Dystrophy (DMD)
Restoring Dystrophin via Exon Skipping Strategies -- PPMD 2022 Annual Conference
Gene Editing for DMD
Webinar: Viltepso - A Treatment Option for Patients Amenable to Exon 53 Skipping (April 2021)
Gene-skipping may be answer for MD kids
In the Pipeline: Restoring Dystrophin - Sarepta Therapeutics (RNA Targeted Therapies)
Gene therapy for Duchenne muscular dystrophy gets FDA approval
In the Pipeline: Next-Gen Exon Skipping (PPMD's 2021 Virtual Annual Conference)
Exon Skipping Motion Graphic
Clinical Trials Antisense Oligonucleotides:Exon Skipping Efficiency In DMD Patient Samples
Avidity: A New Approach to Exon Skipping
Trial Update: Exon 53 NS-065/NCNP-01 - NS Pharma [PPMD's 2017 Connect Conference]
2022 FUTURES Exon Skipping and Read Through Agents Panel
Duchenne Muscular Dystrophy and Dystrophin
AVI Clinical Trial Update (3/2012)
Webinar: Viltepso, An FDA-Approved Treatment for Patients Amenable to Exon 53 Skipping (March 2023)